Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prestige Consumer Healthcare (PBH) Interest Expenses (2016 - 2024)

Historic Interest Expenses for Prestige Consumer Healthcare (PBH) over the last 14 years, with Q4 2024 value amounting to $11.5 million.

  • Prestige Consumer Healthcare's Interest Expenses fell 3088.99% to $11.5 million in Q4 2024 from the same period last year, while for Sep 2025 it was $11.5 million, marking a year-over-year decrease of 7272.16%. This contributed to the annual value of $64.3 million for FY2022, which is 2191.36% down from last year.
  • As of Q4 2024, Prestige Consumer Healthcare's Interest Expenses stood at $11.5 million, which was down 3088.99% from $12.3 million recorded in Q3 2024.
  • In the past 5 years, Prestige Consumer Healthcare's Interest Expenses registered a high of $22.1 million during Q1 2020, and its lowest value of $11.5 million during Q4 2024.
  • In the last 3 years, Prestige Consumer Healthcare's Interest Expenses had a median value of $17.1 million in 2023 and averaged $16.6 million.
  • Its Interest Expenses has fluctuated over the past 5 years, first crashed by 1236.09% in 2020, then plummeted by 3088.99% in 2024.
  • Prestige Consumer Healthcare's Interest Expenses (Quarter) stood at $22.0 million in 2020, then decreased by 24.54% to $16.6 million in 2023, then tumbled by 30.89% to $11.5 million in 2024.
  • Its Interest Expenses stands at $11.5 million for Q4 2024, versus $12.3 million for Q3 2024 and $13.1 million for Q2 2024.